Tag Archives: mrk

Merck’s Keytruda Might Treat Virulent Breast Cancer

Big pharma Merck (MRK) reported Wednesday that its recently approved melanoma drug Keytruda showed promise in a small, early study of patients with a particularly hard-to-treat form of breast cancer. The study gave Keytruda, the first of a new class of drugs called PD-1 inhibitors, to 27 patients with advanced triple-negative breast cancer. Triple-negative means the cancer is not driven by estrogen, progesterone or the HER2 protein, so it doesn’t

Merck-Cubist Deal Is On Despite Patent Setback

Big pharma Merck affirmed Tuesday that it’s going ahead with its $9.5 billion acquisition of biotech Cubist Pharmaceuticals even though Cubist’s lead drug looks to face generic competition sooner than expected. Merck (MRK) stock was down 4.5% in morning trading on the stock market today, while Cubist Pharmaceuticals (CBST) stock was off more than 3.5%. Merck announced the Cubist acquisition Monday morning, hours before a federal judge in Delaware

Merck-Cubist Deal Going Ahead Despite Patent Setback

Big pharma Merck affirmed Tuesday that it’s going ahead with its $9.5 billion acquisition of biotech Cubist Pharmaceuticals even though Cubist’s lead drug looks to face generic competition sooner than expected. Merck (MRK) stock was down 4.5% in morning trading on the stock market today, while Cubist Pharmaceuticals (CBST) stock was off more than 3.5%. Merck announced the Cubist acquisition Monday morning, hours before a federal judge in Delaware